 Biosimilar Pharmaceuticals
"Biosimilar Pharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.
| Descriptor ID |
D059451
|
| MeSH Number(s) |
D20.215.261
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biosimilar Pharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Biosimilar Pharmaceuticals".
This graph shows the total number of publications written about "Biosimilar Pharmaceuticals" by people in this website by year, and whether "Biosimilar Pharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 | | 2018 | 2 | 0 | 2 | | 2019 | 0 | 1 | 1 | | 2020 | 5 | 0 | 5 | | 2021 | 1 | 1 | 2 | | 2022 | 2 | 0 | 2 | | 2023 | 5 | 0 | 5 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Biosimilar Pharmaceuticals" by people in Profiles.
-
Liu A, Xuan A, Socal M, Anderson G, Anderson KE. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019. J Manag Care Spec Pharm. 2024 Jan; 30(1):15-21.
-
Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, Kramer D, Schmider W, Pierre S, Teichert L, Rotthaeuser B, Mukherjee B, Bailey TS. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. Diabetes Obes Metab. 2024 Feb; 26(2):540-547.
-
McBride HJ, Frazer-Abel A, Thiemann S, Lehto SG, Hutterer KM, Liu J. Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD. Ann Hematol. 2023 Dec; 102(12):3299-3309.
-
Anderson KE, Xuan A, Anderson GF, Socal MP. Estimating Changes in Medicare Part D and Commercial Insurer Insulin Spending Amid Planned State-Led Biosimilar Insulin Production in California. JAMA Intern Med. 2023 07 01; 183(7):734-735.
-
White S, Morrow R, Pan I, de Zoeten EF. Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists. J Pediatr Gastroenterol Nutr. 2023 06; 76(6):701-703.
-
Gibbons JB, Laber M, Bennett CL. Humira: the first $20 billion drug. Am J Manag Care. 2023 02; 29(2):78-80.
-
Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022 06; 64:102234.
-
Hussaini SMQ, Gupta A, Anderson KE, Ballreich JM, Nicholas LH, Alexander GC. Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. JAMA Netw Open. 2022 03 01; 5(3):e221117.
-
Bhardwaja B, Klocke S, Ekinci E, Jackson A, Kono S, Olson KL. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System. BioDrugs. 2022 Jan; 36(1):1-11.
-
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 03 02; 19(3):329-359.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|